Abstract
Rhokinase inhibitors is a new class of drug under trial that improve the outflow facility through conventional path way by inhibiting the contractile tone of actin cytoskeleton. They additionally protect trabecular meshwork from oxidative stress, improve Optic Nerve head blood flow, facilitate corneal endothelium wound healing, increase ganglion cell survival and reduce scarring in glaucoma surgery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
